Skip to main
BLTE

BLTE Stock Forecast & Price Target

BLTE Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Belite Bio Inc is making significant strides in the development of novel therapeutics for untreatable eye diseases, as demonstrated by the statistically significant improvement in best corrected visual acuity (BCVA) among treated eyes. The company's market value has notably increased to $3.42 billion, highlighting investor confidence and the potential for future growth, especially with promising results from clinical trials such as the Phase 3 DRAGON trial which showed a 36% reduction in atrophic lesion growth in Stargardt disease. Furthermore, the ongoing exploration of emixustat's efficacy indicates a strong foundational pathway for expanding indications, potentially enhancing the company's overall portfolio in the biopharmaceutical market.

Bears say

Belite Bio Inc faces substantial challenges that contribute to a negative outlook, primarily stemming from the difficulties associated with commercializing its drug tinlarebant, which may require significant price reductions due to its current orphan drug pricing within limited indications. Additionally, the company is projected to incur a cumulative research and development expense exceeding $2.7 billion by 2027, yet may struggle to achieve $3.1 billion in revenue by 2040 following the expiration of the tinlarebant patent, raising concerns about sustainable growth and profitability. Compounded by low confidence in the outcomes of ongoing clinical trials, particularly the Phase 3 study in geographic atrophy, the risks surrounding regulatory approval, market competition, and potential dilution further exacerbate the financial uncertainties facing Belite Bio.

BLTE has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Belite Bio Inc (BLTE) Forecast

Analysts have given BLTE a Buy based on their latest research and market trends.

According to 6 analysts, BLTE has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $175.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $175.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Belite Bio Inc (BLTE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.